Don't compare phase I dose escalation trial result with a more than 200 patients trial result. Wait until phase II single agent reslult from 520.
I hear what you're saying but, if nothing else, the carfilzomib data serves as a cautionary note of the bar that 520 will have to aim for. Also, I'm not certain that ARRY intends to go beyond a much higher 520 dose than what resulted in the 6% response rate. Note what I posted in #msg-57390528, which shows 1.25 mg/m2/day as the MTD without G-CSF given a Grade 4 neutropenia side effect. With G-CSF, 2.0 and 2.25 mg/m2/day were determined to not be tolerated so an intermediate dose of 1.75 mg/m2/day with G-CSF is now being evaluated. So, it doesn't sound like ARRY has a ton of wiggle room to increase the dose of 520.
Market Data 
Markets 
AI
